Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1-Reference-Cited by-同舟云学术

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

Published:2011-05-05 Issue:18 Volume:117 Page:4691-4695
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Rajkumar S. Vincent¹,Harousseau Jean-Luc²,Durie Brian³,Anderson Kenneth C.⁴,Dimopoulos Meletios⁵,Kyle Robert¹,Blade Joan⁶,Richardson Paul⁴,Orlowski Robert⁷,Siegel David⁸,Jagannath Sundar⁹,Facon Thierry¹⁰,Avet-Loiseau Hervé²,Lonial Sagar¹¹,Palumbo Antonio¹²,Zonder Jeffrey¹³,Ludwig Heinz¹⁴,Vesole David⁸,Sezer Orhan¹⁵,Munshi Nikhil C.⁴¹⁶,San Miguel Jesus¹⁷,

Affiliation:

1. Mayo Clinic, Rochester, MN;

2. Universitaire de Nantes, Nantes, France;

3. Cedars-Sinai Medical Center, Los Angeles, CA;

4. Dana-Farber Cancer Institute, Boston, MA;

5. University of Athens, Athens, Greece;

6. Hospital Clinic in Barcelona, Barcelona, Spain;

7. M. D. Anderson Cancer Center, Houston, TX;

8. John Theurer Cancer Center, Hackensack, NJ;

9. Mt Sinai Medical Center, New York, NY;

10. Universitaire de Lille, Lille, France;

11. Winship Cancer Institute/Emory Clinic, Atlanta, GA;

12. University of Torino, Torino, Italy;

13. Karmanos Cancer Center, Detroit, MI;

14. Wilhelminen Hospital, Vienna, Austria;

15. University Medical Center, Hamburg, Germany;

16. Boston Veterans Administration Healthcare System, West Roxbury, MA; and

17. Hospital Universitario, Instituto de Biología Molecular y Celular del Cáncer, Centro de Investigación del Cáncer, Salamanca, Spain

Abstract

Abstract It is essential that there be consistency in the conduct, analysis, and reporting of clinical trial results in myeloma. The goal of the International Myeloma Workshop Consensus Panel 1 was to develop a set of guidelines for the uniform reporting of clinical trial results in myeloma. This paper provides a summary of the current response criteria in myeloma, detailed definitions for patient populations, lines of therapy, and specific endpoints. We propose that future clinical trials in myeloma follow the guidelines for reporting results proposed in this manuscript.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/117/18/4691/1336365/zh801811004691.pdf

Reference15 articles.

1. Multiple myeloma.;Kyle;Blood,2008

2. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma [see comment].;Richardson;N Engl J Med,2005

3. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.;San Miguel;N Engl J Med,2008

4. A phase 2 study of bortezomib in relapsed, refractory myeloma.;Richardson;N Engl J Med,2003

5. Clinically relevant end points and new drug approvals for myeloma.;Anderson;Leukemia,2008

Cited by 868 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase Ib trial of isatuximab, bendamustine, and prednisone in relapsed/refractory multiple myeloma;Annals of Hematology;2024-09-04

2. Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial;The Lancet Haematology;2024-09

3. Efficacy of ixazomib, lenalidomide, dexamethasone regimen in daratumumab‐exposed relapsed/refractory multiple myeloma patients: A retrospective analysis;European Journal of Haematology;2024-08-26

4. Mechanisms of resistance to daratumumab in patients with multiple myeloma;Basic & Clinical Pharmacology & Toxicology;2024-08-26

5. Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study;Blood;2024-08-08